This invention relates to a galenical gel formulation for nasal administration ofneurotransmitters such as dopamine. The special lipophilic or partly lipophilic systemof the invention leads to high bioavailability of the active ingredient in plasmaand brain caused by sustained serum levels and/or direct or partly direct transportfrom nose to the brain.